The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity

ICI-related hepatotoxicity (IRH) is becoming more and more common as immune checkpoint inhibitors (ICIs) have begun to be increasingly approved and used in combination with other anti-tumor drugs worldwide. Steroids are the first choice for the treatment of IRH, but the subsequent optimal treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Hui, Wang, Yang, Qu, Bo, Wei, Qiang, Li, Cuihua, Pan, Chao, Li, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842701/
https://www.ncbi.nlm.nih.gov/pubmed/36623392
http://dx.doi.org/10.1016/j.tranon.2023.101619
_version_ 1784870202288111616
author Xing, Hui
Wang, Yang
Qu, Bo
Wei, Qiang
Li, Cuihua
Pan, Chao
Li, Hui
author_facet Xing, Hui
Wang, Yang
Qu, Bo
Wei, Qiang
Li, Cuihua
Pan, Chao
Li, Hui
author_sort Xing, Hui
collection PubMed
description ICI-related hepatotoxicity (IRH) is becoming more and more common as immune checkpoint inhibitors (ICIs) have begun to be increasingly approved and used in combination with other anti-tumor drugs worldwide. Steroids are the first choice for the treatment of IRH, but the subsequent optimal treatment algorithm remains unclear if the disease progresses to steroid-refractory IRH. Therefore, in this paper we reviewed all the pertinent literature on steroid-refractory IRH to the greatest extent possible in an attempt to provide information on which to base an update of the treatment algorithm for steroid-refractory IRH.
format Online
Article
Text
id pubmed-9842701
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-98427012023-01-24 The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity Xing, Hui Wang, Yang Qu, Bo Wei, Qiang Li, Cuihua Pan, Chao Li, Hui Transl Oncol Review ICI-related hepatotoxicity (IRH) is becoming more and more common as immune checkpoint inhibitors (ICIs) have begun to be increasingly approved and used in combination with other anti-tumor drugs worldwide. Steroids are the first choice for the treatment of IRH, but the subsequent optimal treatment algorithm remains unclear if the disease progresses to steroid-refractory IRH. Therefore, in this paper we reviewed all the pertinent literature on steroid-refractory IRH to the greatest extent possible in an attempt to provide information on which to base an update of the treatment algorithm for steroid-refractory IRH. Neoplasia Press 2023-01-07 /pmc/articles/PMC9842701/ /pubmed/36623392 http://dx.doi.org/10.1016/j.tranon.2023.101619 Text en © 2023 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Xing, Hui
Wang, Yang
Qu, Bo
Wei, Qiang
Li, Cuihua
Pan, Chao
Li, Hui
The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
title The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
title_full The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
title_fullStr The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
title_full_unstemmed The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
title_short The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
title_sort current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842701/
https://www.ncbi.nlm.nih.gov/pubmed/36623392
http://dx.doi.org/10.1016/j.tranon.2023.101619
work_keys_str_mv AT xinghui thecurrentstatusofsteroidrefractoryimmunecheckpointinhibitorrelatedhepatotoxicity
AT wangyang thecurrentstatusofsteroidrefractoryimmunecheckpointinhibitorrelatedhepatotoxicity
AT qubo thecurrentstatusofsteroidrefractoryimmunecheckpointinhibitorrelatedhepatotoxicity
AT weiqiang thecurrentstatusofsteroidrefractoryimmunecheckpointinhibitorrelatedhepatotoxicity
AT licuihua thecurrentstatusofsteroidrefractoryimmunecheckpointinhibitorrelatedhepatotoxicity
AT panchao thecurrentstatusofsteroidrefractoryimmunecheckpointinhibitorrelatedhepatotoxicity
AT lihui thecurrentstatusofsteroidrefractoryimmunecheckpointinhibitorrelatedhepatotoxicity
AT xinghui currentstatusofsteroidrefractoryimmunecheckpointinhibitorrelatedhepatotoxicity
AT wangyang currentstatusofsteroidrefractoryimmunecheckpointinhibitorrelatedhepatotoxicity
AT qubo currentstatusofsteroidrefractoryimmunecheckpointinhibitorrelatedhepatotoxicity
AT weiqiang currentstatusofsteroidrefractoryimmunecheckpointinhibitorrelatedhepatotoxicity
AT licuihua currentstatusofsteroidrefractoryimmunecheckpointinhibitorrelatedhepatotoxicity
AT panchao currentstatusofsteroidrefractoryimmunecheckpointinhibitorrelatedhepatotoxicity
AT lihui currentstatusofsteroidrefractoryimmunecheckpointinhibitorrelatedhepatotoxicity

Ejemplares similares